CTLT Technical Analysis
As of date:11/23/2022
CTLT stock price:42.18
CTLT 50 DMA:64.80
CTLT 200 DMA:93.10
CTLT MACD (200-50):28.30
CTLT RSI:49.84
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)49.84
Extremely
Oversold

Also see:
CTLT Market Cap History
CTLT Shares Outstanding History
CTLT YTD Return

Try ChartSweeps today
Quotes delayed 20 minutes

Email EnvelopeFree CTLT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Bullish Two Hundred Day Moving Average Cross - FLIC
Wednesday, November 23, 4:30 PM


NovaGold Resources Breaks Above 200-Day Moving Average - Bullish for NG
Wednesday, November 23, 4:23 PM


Bullish Two Hundred Day Moving Average Cross - VST
Wednesday, November 23, 4:14 PM


Bullish Two Hundred Day Moving Average Cross - WPM
Wednesday, November 23, 4:08 PM


TILT Makes Bullish Cross Above Critical Moving Average
Wednesday, November 23, 4:06 PM


Bullish Two Hundred Day Moving Average Cross - RELX
Wednesday, November 23, 4:06 PM


FLCA Shares Cross Above 200 DMA
Wednesday, November 23, 4:05 PM


Abercrombie & Fitch (ANF) Shares Cross Above 200 DMA
Wednesday, November 23, 4:05 PM


CAL Makes Notable Cross Below Critical Moving Average
Wednesday, November 23, 4:05 PM


IMTM Crosses Above Key Moving Average Level
Wednesday, November 23, 4:05 PM


EFAX Makes Bullish Cross Above Critical Moving Average
Wednesday, November 23, 4:05 PM


Invesco RAFI Strategic Developed ex-US (ISDX) Shares Cross Above 200 DMA
Wednesday, November 23, 4:05 PM


AEM Makes Bullish Cross Above Critical Moving Average
Wednesday, November 23, 4:04 PM


PJUN Crosses Above Key Moving Average Level
Wednesday, November 23, 4:04 PM


VEA Makes Bullish Cross Above Critical Moving Average
Wednesday, November 23, 4:04 PM


More Technical Analysis News

CTLT Technical AnalysisCTLT RSI
Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.

When researching a stock like Catalent, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from CTLT Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for CTLT stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
CTLT DMACTLT MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Catalent (CTLT) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

CVS Technical Analysis
DGX Technical Analysis
DHR Technical Analysis
DVA Technical Analysis
DXCM Technical Analysis
ELV Technical Analysis
EW Technical Analysis
GILD Technical Analysis
HCA Technical Analysis
HOLX Technical Analysis
More Healthcare companies »

 

CTLT Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2022, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.